GT201500168A - Polipéptidos estabilizados del factor de crecimiento tipo insulina - Google Patents
Polipéptidos estabilizados del factor de crecimiento tipo insulinaInfo
- Publication number
- GT201500168A GT201500168A GT201500168A GT201500168A GT201500168A GT 201500168 A GT201500168 A GT 201500168A GT 201500168 A GT201500168 A GT 201500168A GT 201500168 A GT201500168 A GT 201500168A GT 201500168 A GT201500168 A GT 201500168A
- Authority
- GT
- Guatemala
- Prior art keywords
- polipeptides
- stabilized
- growth factor
- type growth
- insulin type
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 239000003102 growth factor Substances 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 3
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE UBICA EN EL CAMPO DE LAS MODIFICACIONES DEL IGF-1. EN PARTICULAR, SE REFIERE A POLIPÉPTIDOS DE IGF-1 MODIFICADOS Y A POLIPÉPTIDOS PRECURSORES DE IGF-1 MODIFICADOS, EN DONDE SE PREVIENE LA DISOCIACIÓN DE PÉPTIDOS-E. LA INVENCIÓN TAMBIÉN SE REFIERE AL USO DE ESOS POLIPÉPTIDOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS MUSCULARES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738475P | 2012-12-18 | 2012-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201500168A true GT201500168A (es) | 2016-01-21 |
Family
ID=50073229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201500168A GT201500168A (es) | 2012-12-18 | 2015-06-18 | Polipéptidos estabilizados del factor de crecimiento tipo insulina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10167329B2 (es) |
| EP (2) | EP3626735A1 (es) |
| JP (1) | JP6499080B2 (es) |
| KR (1) | KR102182523B1 (es) |
| CN (1) | CN105121462B (es) |
| AP (1) | AP2015008440A0 (es) |
| AU (1) | AU2013365796B2 (es) |
| BR (1) | BR112015013708B1 (es) |
| CA (1) | CA2894976C (es) |
| CL (1) | CL2015001708A1 (es) |
| CR (2) | CR20200079A (es) |
| CU (1) | CU24308B1 (es) |
| CY (1) | CY1122309T1 (es) |
| DK (1) | DK2935320T3 (es) |
| EA (1) | EA034356B1 (es) |
| EC (1) | ECSP15031046A (es) |
| ES (1) | ES2756330T3 (es) |
| GT (1) | GT201500168A (es) |
| HR (1) | HRP20191965T1 (es) |
| HU (1) | HUE047386T2 (es) |
| IL (1) | IL239387A0 (es) |
| LT (1) | LT2935320T (es) |
| MA (1) | MA38153B1 (es) |
| MX (1) | MX363021B (es) |
| MY (1) | MY174820A (es) |
| NZ (1) | NZ708091A (es) |
| PE (2) | PE20151612A1 (es) |
| PH (1) | PH12015501271B1 (es) |
| PL (1) | PL2935320T3 (es) |
| PT (1) | PT2935320T (es) |
| RS (1) | RS59545B1 (es) |
| SA (1) | SA515360603B1 (es) |
| SG (1) | SG11201503782PA (es) |
| SI (1) | SI2935320T1 (es) |
| TN (1) | TN2015000182A1 (es) |
| WO (1) | WO2014097116A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2926173A1 (en) * | 2013-10-02 | 2015-04-09 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| BR112018067747A2 (pt) * | 2016-03-04 | 2019-01-08 | Shire Human Genetic Therapies | proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| TW202019458A (zh) * | 2018-06-27 | 2020-06-01 | 美商裘美娜治療公司 | 肝素相關多肽及其用途 |
| CN109053875B (zh) * | 2018-08-31 | 2021-06-29 | 重庆大学 | 突变型igf-1、重组质粒、重组蛋白及应用 |
| RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
| CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
| WO2021133822A1 (en) | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| CA3223707A1 (en) | 2021-06-21 | 2022-12-29 | Hanadie Yousef | Regenerative polypeptides and uses thereof |
| WO2025106529A2 (en) * | 2023-11-14 | 2025-05-22 | Cavalry Biosciences, Inc. | Compositions for targeting muscle cells and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP2002535967A (ja) * | 1999-01-06 | 2002-10-29 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ変異体 |
| DK1141014T3 (da) | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
| EP1456360B1 (en) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
| WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| EP2241575B1 (en) * | 2005-01-07 | 2015-06-24 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| JP2009539805A (ja) | 2006-06-09 | 2009-11-19 | ノバルティス アクチエンゲゼルシャフト | 安定化されたインスリン様増殖因子ポリペプチド |
| CN101466398A (zh) * | 2006-06-09 | 2009-06-24 | 诺瓦提斯公司 | 稳定的胰岛素样生长因子多肽 |
| EP3075858B1 (en) | 2007-12-21 | 2020-01-29 | Novartis Ag | Mammalian expression vector |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| WO2011011073A1 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| US10030063B2 (en) | 2012-12-18 | 2018-07-24 | Novartis Ag | Production of therapeutic proteins in genetically modified mammalian cells |
| CA2926173A1 (en) | 2013-10-02 | 2015-04-09 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
-
2013
- 2013-12-16 PE PE2015001039A patent/PE20151612A1/es not_active Application Discontinuation
- 2013-12-16 PL PL13828987T patent/PL2935320T3/pl unknown
- 2013-12-16 DK DK13828987T patent/DK2935320T3/da active
- 2013-12-16 PT PT138289871T patent/PT2935320T/pt unknown
- 2013-12-16 CA CA2894976A patent/CA2894976C/en active Active
- 2013-12-16 EP EP19191570.1A patent/EP3626735A1/en not_active Withdrawn
- 2013-12-16 NZ NZ708091A patent/NZ708091A/en not_active IP Right Cessation
- 2013-12-16 MA MA38153A patent/MA38153B1/fr unknown
- 2013-12-16 LT LT13828987T patent/LT2935320T/lt unknown
- 2013-12-16 RS RS20191416A patent/RS59545B1/sr unknown
- 2013-12-16 EP EP13828987.1A patent/EP2935320B1/en active Active
- 2013-12-16 HU HUE13828987A patent/HUE047386T2/hu unknown
- 2013-12-16 BR BR112015013708-3A patent/BR112015013708B1/pt not_active IP Right Cessation
- 2013-12-16 CR CR20200079A patent/CR20200079A/es unknown
- 2013-12-16 KR KR1020157018991A patent/KR102182523B1/ko active Active
- 2013-12-16 ES ES13828987T patent/ES2756330T3/es active Active
- 2013-12-16 HR HRP20191965TT patent/HRP20191965T1/hr unknown
- 2013-12-16 AU AU2013365796A patent/AU2013365796B2/en not_active Ceased
- 2013-12-16 PE PE2019002049A patent/PE20200894A1/es unknown
- 2013-12-16 MX MX2015007932A patent/MX363021B/es unknown
- 2013-12-16 SI SI201331611T patent/SI2935320T1/sl unknown
- 2013-12-16 SG SG11201503782PA patent/SG11201503782PA/en unknown
- 2013-12-16 CU CUP2015000064A patent/CU24308B1/es unknown
- 2013-12-16 EA EA201591165A patent/EA034356B1/ru not_active IP Right Cessation
- 2013-12-16 WO PCT/IB2013/060985 patent/WO2014097116A1/en not_active Ceased
- 2013-12-16 MY MYPI2015001207A patent/MY174820A/en unknown
- 2013-12-16 US US14/651,686 patent/US10167329B2/en active Active
- 2013-12-16 CN CN201380066090.8A patent/CN105121462B/zh active Active
- 2013-12-16 AP AP2015008440A patent/AP2015008440A0/xx unknown
- 2013-12-16 JP JP2015547255A patent/JP6499080B2/ja active Active
-
2015
- 2015-05-08 TN TNP2015000182A patent/TN2015000182A1/fr unknown
- 2015-06-04 PH PH12015501271A patent/PH12015501271B1/en unknown
- 2015-06-11 IL IL239387A patent/IL239387A0/en active IP Right Grant
- 2015-06-17 CL CL2015001708A patent/CL2015001708A1/es unknown
- 2015-06-17 SA SA515360603A patent/SA515360603B1/ar unknown
- 2015-06-18 CR CR20150324A patent/CR20150324A/es unknown
- 2015-06-18 GT GT201500168A patent/GT201500168A/es unknown
- 2015-07-17 EC ECIEPI201531046A patent/ECSP15031046A/es unknown
-
2019
- 2019-11-19 CY CY20191101212T patent/CY1122309T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201500168A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
| CR20150358A (es) | Derivados de exendina-4 fucionalizada | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| GT201300215A (es) | Inhibidores de glucosilceramida sintasa | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| CL2014001993A1 (es) | Uso de melatonina para el tratamiento de trastornos del ritmo circadiano | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX2015011769A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| EA201591427A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| BR112014028413A2 (pt) | usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 . | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| MX356052B (es) | Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CR20170376A (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida | |
| MX2018005158A (es) | Compuestos para el tratamiento de trastornos hipoproliferativos. | |
| MX2015008454A (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
| CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma | |
| ITUB20169928A1 (it) | Formulazioni farmaceutiche per il trattamento del diabete | |
| DOP2015000290A (es) | Benzoxazoles sustituidos | |
| BR112016029044A2 (pt) | ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite |